Velusetrag for the treatment of chronic constipation.

Abstract

INTRODUCTION:

Chronic constipation is a frequent complaint in daily clinical practice. Notwithstanding the availability of numerous drugs, its treatment it is still unsatisfactory. However, new emerging treatments are in the pipeline and some drugs seem to be promising; among these velusetrag, a selective 5-HT4 receptors agonist.

AREAS COVERED:

An in depth Medline literature search was performed concerning topics related to the treatment of constipated patients with velusetrag. In addition, abstracts concerning the topic were searched by hand in our libraries.

EXPERT OPINION:

After analyzing the available data, the authors feel that velusetrag may likely improve symptoms and the quality of life of chronically constipated subjects. However, additional data is needed to fully understand the safety and efficacy of velusetrag, particularly in patients on long-term therapy. Thanks to the once-daily dosing and the pharmacologic properties, velusetrag could be used as a single agent or in association with other drugs. In the future, this drug holds the potential to be an effective adjunct to the therapeutic armamentarium for chronic constipation.

• Authors: Gabrio Bassotti, Dario Gambaccini, Massimo Bellini
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 25 Issue 8 Pg. 985-90 (Aug 2016) ISSN: 1744-7658 [Electronic] England
• PMID: 27269187 (Publication Type: Journal Article, Review)

Chemical References

• Azabicyclo Compounds
• Serotonin 5-HT4 Receptor Agonists
• TD-5108

Topics

• Animals
• Azabicyclo Compounds (adverse effects, pharmacology, therapeutic use)
• Chronic Disease
• Constipation (drug therapy)
• Humans
• Quality of Life
• Serotonin 5-HT4 Receptor Agonists (adverse effects, pharmacology, therapeutic use)